NCT05983198 - Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

November 19, 2026

Study Completion Date

November 5, 2029

Conditions

Prostate Cancer

Interventions

DRUG

225Ac-PSMA-R2

PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide

RADIATION

68Ga-PSMA-R2

Kit for radiopharmaceutical preparation

RADIATION

68Ga-PSMA-11

Kit for radiopharmaceutical preparation

Trial Locations (12)

2010

RECRUITING

Novartis Investigative Site, Darlinghurst

3004

RECRUITING

Novartis Investigative Site, Melbourne

21034

RECRUITING

Novartis Investigative Site, Dijon

44093

RECRUITING

Novartis Investigative Site, Nantes

44805

RECRUITING

Novartis Investigative Site, Saint-Herblain

49503

RECRUITING

BAMF Health, Grand Rapids

54511

RECRUITING

Novartis Investigative Site, Vandœuvre-lès-Nancy

55905

RECRUITING

Mayo Clinic Rochester, Rochester

63011

RECRUITING

Novartis Investigative Site, Clermont-Ferrand

69373

RECRUITING

Novartis Investigative Site, Lyon

H2X 1R9

RECRUITING

Novartis Investigative Site, Montreal

H3T 1E2

RECRUITING

Novartis Investigative Site, Montreal